Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen unrecognized Tax Benefits (UTB Rollforward — IRS Transfer Pricing Dispute) — Ending Gross Balance ($M) ($M)
Form 10-K Income Taxes Note — Unrecognized Tax Benefits Rollforward (XBRL)
Latest, FY2025
4,371
Period ended Dec 31, 2025
Change on a year earlier
+4.5%
4,184 in FY2024
History
11 years
Since FY2015
Sources
7
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Unrecognized Tax Benefits (UTB Rollforward — IRS Transfer Pricing Dispute) — Ending Gross Balance ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4,371 | +4.5% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 4,184 | +4.3% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 4,012 | +6.4% | Form 10-K (filed 2026-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 3,770 | +6.3% | Form 10-K (filed 2026-02-13) ↗ |
| FY2021 | Dec 31, 2021 | 3,546 | +5.8% | Form 10-K (filed 2025-02-14) ↗ |
| FY2020 | Dec 31, 2020 | 3,352 | +2.0% | Form 10-K (filed 2024-02-14) ↗ |
| FY2019 | Dec 31, 2019 | 3,287 | +7.4% | Form 10-K (filed 2023-02-09) ↗ |
| FY2018 | Dec 31, 2018 | 3,061 | +3.7% | Form 10-K (filed 2022-02-16) ↗ |
| FY2017 | Dec 31, 2017 | 2,953 | +16.1% | Form 10-K (filed 2021-02-09) ↗ |
| FY2016 | Dec 31, 2016 | 2,543 | +20.3% | Form 10-K (filed 2019-02-13) ↗ |
| FY2015 | Dec 31, 2015 | 2,114 | – | Form 10-K (filed 2019-02-13) ↗ |
Breakdown
What makes up unrecognized tax benefits (utb rollforward — irs transfer pricing dispute) — ending gross balance ($m)
- Unrecognized Tax Benefits Liability Affecting Effective Tax Rate ($M)2,690 · FY2025
- UTB Additions Based on Tax Positions Related to Current Year ($M)190 · FY2025
- UTB Additions for Tax Positions of Prior Years ($M)14 · FY2025
- UTB Reductions for Tax Positions of Prior Years ($M)13 · FY2025
- UTB Reductions from Settlements with Taxing Authorities ($M)4 · FY2025
- UTB Reductions from Lapse of Statute of Limitations ($M)0 · FY2025
- Accrued Interest and Penalties on Unrecognized Tax Benefits ($M)1,900 · FY2025
- Gross Interest and Penalties Expense on Unrecognized Tax Benefits ($M)264 · FY2025
Cite this data
StockData. (2026). Amgen Unrecognized Tax Benefits (UTB Rollforward — IRS Transfer Pricing Dispute) — Ending Gross Balance ($M) ($M), annual FY2015–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/utb_total
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.